Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$65.87 USD

65.87
249,201

+0.44 (0.67%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $66.51 +0.64 (0.97%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Corcept (CORT) Completes Enrollment in Phase II ALS Study

by Zacks Equity Research

The phase II DAZALS study is evaluating Corcept's (CORT) dazucorilant for treating patients with amyotrophic lateral sclerosis. Enrollment in the study is already complete.

Zacks Equity Research

Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug

by Zacks Equity Research

The FDA places a clinical hold on Neumora's (NMRA) phase I study evaluating NMRA-266 for some types of neuropsychiatric disorders. Shares of the company fall on the news.

Zacks Equity Research

J&J (JNJ) Q1 Earnings Beat Estimates, Sales Miss, MedTech Soft

by Zacks Equity Research

J&J (JNJ) beats estimates for first-quarter earnings but misses the same for sales. It tightens its sales and earnings growth expectations for 2024.

Zacks Equity Research

Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug

by Zacks Equity Research

Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.

Zacks Equity Research

Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why

by Zacks Equity Research

Enlivex (ENLV) plunges after it shares mixed results from a mid-stage study evaluating its lead drug as a potential treatment for sepsis.

Zacks Equity Research

Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors

by Zacks Equity Research

Janux (JANX) stock surges after some reports claim that the company is exploring opportunities for a potential sale following buyout offers from big pharma companies.

Zacks Equity Research

Why ANI (ANIP) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids

by Zacks Equity Research

The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.

Zacks Equity Research

ANI Pharmaceuticals (ANIP) Stock Moves -0.13%: What You Should Know

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) closed at $66.96 in the latest trading session, marking a -0.13% move from the prior day.

Zacks Equity Research

Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study

by Zacks Equity Research

Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.

Zacks Equity Research

Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma

by Zacks Equity Research

The FDA bestows an Orphan Drug designation to Lisata's (LSTA) lead investigational product candidate, LSTA1, for the treatment of osteosarcoma. Stock rises.

Zacks Equity Research

Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML

by Zacks Equity Research

The FDA bestows a Fast Track Designation to Syros' (SYRS) pipeline candidate, tamibarotene, in combination with venetoclax and azacitidine to treat newly diagnosed acute myeloid leukemia. Stock rises.

Zacks Equity Research

Vincerx (VINC) Tumbles on Results From Cancer Therapy Study

by Zacks Equity Research

Though early-stage results on Vincerx's (VINC) experimental drug did show signs of anti-tumor activity, the share price drops as some analysts stated that the results were below expectations.

Zacks Equity Research

Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data

by Zacks Equity Research

Bristol Myers' (BMY) Krazati, in combination with cetuximab, demonstrates clinically meaningful activity as a targeted treatment option for patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer.

Zacks Equity Research

Corcept (CORT) Completes Enrollment in Ovarian Cancer Study

by Zacks Equity Research

The phase III ROSELLA study is evaluating Corcept's (CORT) relacorilant plus nab-paclitaxel for treating recurrent, platinum-resistant ovarian cancer. Enrollment in the study has been completed.

Zacks Equity Research

Is it a Good Idea to Invest in ADMA Biologics (ADMA) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in ADMA Biologics (ADMA) stock may turn out to be a prudent move now.

Zacks Equity Research

Here's Why You Should Invest in Entera Bio (ENTX) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why buying Entera Bio (ENTX) stock now may turn out to be a prudent move.

Zacks Equity Research

Palatin (PTN) Up 15% on Results From Dry Eye Disease Study

by Zacks Equity Research

A late-stage study data shows that treatment with Palatin's (PTN) experimental dry eye disease drug achieved statistically significant and clinically meaningful improvements across multiple symptom endpoints.

Zacks Equity Research

Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why

by Zacks Equity Research

Iovance (IOVA) surges on the recent FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.

Zacks Equity Research

Bausch (BHC) Starts Litigation Against Amneal for Xifaxan

by Zacks Equity Research

Bausch (BHC) initiates litigation against Amneal Pharmaceuticals and its subsidiaries over a generic version of its lead drug Xifaxan.

Zacks Equity Research

MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why

by Zacks Equity Research

MindMed's (MNMD) progress with the development of its lead candidate MM120 for treating generalized anxiety disorder has been encouraging, leading the stock to rise during this time.

Zacks Equity Research

Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress

by Zacks Equity Research

Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.

Zacks Equity Research

AstraZeneca's (AZN) Imfinzi Improves Survival in SCLC Study

by Zacks Equity Research

AstraZeneca's (AZN) Imfinzi improves overall survival and progression-free survival for patients with limited-stage small cell lung cancer in the phase III ADRIATIC study.

Zacks Equity Research

Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study

by Zacks Equity Research

Candel's (CADL) CAN-2409 demonstrates improvements in estimated median overall survival versus the control group in treating borderline resectable pancreatic ductal adenorcarcinoma. The stock rises.

Zacks Equity Research

Wall Street Analysts Think ANI (ANIP) Is a Good Investment: Is It?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in ANI (ANIP). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?